Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Palisade Bio, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 16 | 8 | −8 |
| SharesConverted for a 1-for-15 split | 64.4K | 65.8K | +1.43K (+2.2%) |
| Value | $384.6K | $297.7K | −$87.0K (−22.6%) |
New holders (2)
Institutions that held Palisade Bio, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tower Research Capital LLC (TRC) | 738 | $3.32K | 0.00% |
| Bank of America Corp | 5 | $22 | 0.00% |
Sold out (10)
Institutions that held Palisade Bio, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Vanguard Group Inc | 68,054 | $27.2K |
| Geode Capital Management, LLC | 34,448 | $13.7K |
| HRT Financial LP | 32,326 | $12.0K |
| Two Sigma Securities, LLC | 28,208 | $11.3K |
| State Street Corp | 22,463 | $8.96K |
| Millennium Management LLC | 18,200 | $7.26K |
| Orion Capital Management LLC | 299 | $119 |
| BFSG, LLC | 40 | $16 |
| BlackRock Inc. | 9 | $4 |
| FMR LLC | 3 | $1 |